Puridify

Puridify develops innovative bioprocessing platform technologies, specializing in nanofiber-based purification for the biopharmaceutical industry. Its core product, FibroSelect, offers a cost-effective manufacturing solution for various biopharmaceutical products. This technology significantly enhances purification, addressing key bottlenecks in biomanufacturing to improve efficiency and reduce expenses.

The company originates as a 2013 spin-out from University College London, leveraging advanced academic research in material science for biological applications. The founding insight targets overcoming traditional biopurification limitations by utilizing novel fibrous materials, establishing a strong scientific basis for its distinct technological approach.

Puridify’s solutions serve the biopharmaceutical sector, assisting manufacturers in streamlining production of existing and emerging therapies. Its vision centers on enabling more accessible, efficient biomanufacturing globally. By advancing purification, Puridify accelerates the development and commercialization of vital biopharmaceutical medicines, fostering optimized drug production.

High-Level Overview

Puridify was a UK-based biotech startup that developed FibroSelect, a nanofiber-based platform purification technology for biopharmaceutical manufacturing. It targeted biotherapeutic producers by addressing high costs and inefficiencies in downstream purification processes, using 3D nanofibers for faster mass transfer, 10x higher efficiency, and up to 25% cost reductions compared to traditional bead resins and chromatography membranes.[1][2][3][4][5] The technology enabled scalable, flexible biomanufacturing, reducing unit costs from $300-1,000 per gram and saving drug companies £700,000-£2.7 million per batch, with early traction leading to its acquisition by GE Healthcare in 2017.[3][5][6]

Origin Story

Puridify emerged as a spinout from University College London’s (UCL) Department of Biochemical Engineering, with technology rooted in academic research on nanofiber purification.[3][4] Co-founder Oliver Hardick led the company, supported by Innovate UK funding for prototype development, which secured UK patents (one advanced internationally).[5] The idea addressed the mismatch between surging biotherapeutic demand—up 100-fold in 20 years—and outdated small-scale manufacturing methods.[5] Pivotal early funding included a £850,000 ($1.4m) seed round in 2014 co-led by Touchstone Innovations (now Imperial Innovations), SR One (GlaxoSmithKline’s VC arm), and UCL Business, followed by a $3.4m Series A in 2015 from the same investors, totaling $4.9m raised.[3][5][6] GSK extended evaluations of FibroSelect, validating its promise with biomanufacturers.[7]

Core Differentiators

• Nanofiber Technology (FibroSelect): Employed 3D nanofibers for chromatographic separation, offering 10x faster mass transfer, superior scalability, and ease of use over porous beads, boosting productivity in process development and small-scale manufacturing.[1][2][3][4]
• Cost and Efficiency Gains: Reduced biotherapeutic production costs by 25%, with flexible processing strategies for new biomanufacturing paradigms.[1][2][5]
• Industry Validation: Developed in collaboration with leading biomanufacturers like GSK, achieving promising industrial results and patent protection before acquisition.[3][5][7]
• Integration Potential: Complementary to existing GE Healthcare products, enabling seamless commercialization post-acquisition.[3][4][10]

Role in the Broader Tech Landscape

Puridify rode the wave of exploding biopharmaceutical demand, where manufacturing bottlenecks limited access to high-value drugs like monoclonal antibodies despite a 100-fold market growth over two decades.[5] Its timing aligned with pressures for cost-effective, scalable bioprocessing amid rising complexity in biologics production.[1][2] Market forces favoring nanofiber innovations—driven by needs for speed, flexibility, and lower costs—positioned it well in the $20B+ downstream purification sector.[3] By advancing UCL research to industry-ready tech, Puridify influenced the ecosystem through investor milestones (e.g., SR One, Touchstone) and GE's integration, accelerating nanofiber adoption in global biomanufacturing.[3][4][6]

Quick Take & Future Outlook

Post-2017 acquisition, Puridify's FibroSelect integrated into GE Healthcare's (now GE HealthCare) BioProcess portfolio, with continued investment for commercialization and staff retention at UCL-linked sites.[3][4][10] Next steps likely involve broader rollout in biopharma supply chains, leveraging GE's scale for global adoption. Trends like AI-optimized bioprocessing, personalized medicines, and capacity expansions for mRNA/cell therapies will amplify its impact, evolving nanofiber tech into a standard for efficient, high-volume production. This UCL spinout's journey—from lab to corporate powerhouse—exemplifies how targeted biotech innovations transform manufacturing constraints into ecosystem enablers.[3][5]